Dafne Quixabeira

7PUBLICATIONS
27CO-AUTHORS
Molecular targetsSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 10, 2026
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.

Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari

|Mar 28, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Santeri A Pakola, Katriina J Peltola, James H A Clubb

|Nov 10, 2023
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.

D C A Quixabeira, S Pakola, E Jirovec

|Sep 04, 2023
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.

D C A Quixabeira, E Jirovec, S Pakola

|Aug 23, 2022
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.

Camilla Heiniö, James Clubb, Tatiana Kudling

|Jan 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.

Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos

Pageof 2

Frequent Collaborators

6 joint publications

Tatiana V Kudling

6 joint publications

Akseli Hemminki

4 joint publications

Santeri Artturi Pakola

4 joint publications

Victor Cervera-Carrascon